Shareholder rights law firm Robbins LLP is investigating Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws. Verrica is a dermatology therapeutics company that develops medications for viral skin diseases requiring medical intervention.

If you would like more information about our investigation of Verrica Pharmaceuticals Inc.'s misconduct, click here.

What is this Case About: Verrica Pharmaceuticals Inc. (VRCA) Received a Third Complete Response Letter from the FDA relating to its New Drug Application for VP-102

Verrica has spent several years working to bring to market VP-102, the Company's investigational, proprietary, drug-device combination for the treatment of molluscum contagiosum. However, several challenges have prevented this from happening. Verrica received its first Complete Response Letter (CRL) regarding the New Drug Application (NDA) in July 2020 and its second in September 2021. On May 24, 2022, Verrica received yet another CRL from the FDA related to its NDA for VP-102. On this news, the Company's stock price fell 63.85%, to close at $2.01 per share on May 25, 2022.

Next Steps: If you own shares of Verrica Pharmaceuticals Inc. (VRCA), you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas

(800) 350-6003

adumas@robbinsllp.com

Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Verrica Pharmaceuticals Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220609006077/en/